Live attenuated measles, mumps, rubella, and varicella zoster virus vaccine (Priorix-Tetra™)

Pediatric Drugs

Volumn 10, Issue 5, 2008, Pages 337-347

  Dhillon, Sohita ^a,b   Curran, Monique P ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Adis Drug Profiles; Children; MMR varicella zoster virus vaccine, immunogenicity; Research and development

Indexed keywords

ANTIPYRETIC AGENT; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; MEASLES MUMPS RUBELLA VACCINE; MEASLES MUMPS RUBELLA VARICELLA ZOSTER VACCINE; ORAL POLIOMYELITIS VACCINE; PRIORIX TETRA; VARICELLA ZOSTER VACCINE;

CHICKENPOX; CHILD; CLINICAL TRIAL; DRUG INDICATION; DRUG TOLERABILITY; FEVER; HUMAN; IMMUNOGENICITY; INFANT; INJECTION SITE DISCOLORATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; MEASLES; MUMPS; PRIORITY JOURNAL; RASH; REVIEW; RUBELLA; SEROCONVERSION; SINGLE DRUG DOSE; SKIN REDNESS;

CHILD; DRUG COMBINATIONS; HERPES ZOSTER VACCINE; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MEASLES-MUMPS-RUBELLA VACCINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VACCINES, ATTENUATED;

EID: 50649085027     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200810050-00007     Document Type: Review

References (21)

1. Centers for Disease Control and Prevention. Vaccines timeline [online]. Available from URL: http://www.cdc.gov/nip/vaccine/vacc-timeline.htm [Accessed 2008 May 26]
2. World Health Organization. Immunization, vaccines and biologicals [online]. Available from URL: http://www.who.int/features/factfiles/ immunization/en/index.html [Accessed 2008 May 26]
3. United Nations Children's Fund. Immunization summary: the 2007 edition [online]. Available from URL: http://www.unicef.org/publications/files/ Immunization_Summary_2007.pdf [Accessed 2008 Mar 18]
4. Kroger AT, Atkinson WL, Marcuse EK, et al. General recommendations on immunization; recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2006; 55 (RR-15): 1-47
5. World Health Organization. Measles vaccines. Wkly Epidemiol Rec 2004; 79 (14): 130-42
6. World Health Organization. Mumps virus vaccines. Wkly Epidemiol Rec 2001; 76 (45): 346-55
7. World Health Organization. Rubella vaccines. Wkly Epidemiol Rec 2000; 75 (20): 161-9
8. Centers for Disease Control and Prevention. Notice to readers: updated recommendations of the advisory committee on immunization practices (ACIP) for the control and elimination of mumps. MMWR Weekly 2006 Jun 9; 55 (22): 629-30
9. Knuf M, Habermehl P, Zepp F, et al. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. Pediatr Infect Dis J 2006; 25 (1): 12-8
10. World Health Organization. Varicella vaccines. Wkly Epidemiol Rec 1998; 73 (32): 241-8
11. Galil K, Lee B, Strine T, et al. Outbreak of varicella at a day-care center despite vaccination. N Engl J Med 2002; 347 (24): 1909-15
12. Dworkin MS, Jennings CE, Roth-Thomas J, et al. An outbreak of varicella among children attending preschool and elementary school in Illinois. Clin Infect Dis 2002; 35 (1): 102-4
13. Kuter B, Matthews H, Shinefield H, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J 2004; 23 (2): 132-7
14. Stuck B, Stehr K, Bock HL. Concomitant administration of varicella vaccine with combined measles, mumps, and rubella vaccine in healthy children aged 12 to 24 months of age. Asian Pac J Allergy Immunol 2002; 20: 113-20
15. Schuster V, Otto W, Maurer L, et al. Immunogenicity and safety assessments after one or two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. Pediatr Infect Dis J 2008; 27 (8): 724-30
16. Goh P, Lim FS, Han HH, et al. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age. Infection 2007; 35 (5): 326-33
17. Nolan T, McIntyre P, Roberton D, et al. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine. Vaccine 2002; 21: 281-9
18. Zepp F, Otto W, Helm K, et al. Antibody persistence and varicella breakthrough cases assessment two years after administration of measles-mumps-rubella-varicella (MMRV) vaccine in children aged 11-23 months [abstract no. 619]. 25th Annual Meeting of the European Society for Pediatric Infectious Diseases; 2-4 May 2007; Porto
19. Zepp F, Behre U, Kindler K, et al. Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in healthy children aged 12-23 months. Eur J Pediatr 2007 May 31; 166 (8): 857-64
20. Vesikari T, Baer M, Willems P. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years. Pediatr Infect Dis J 2007 Feb; 26 (2): 153-8
21. GlaxoSmithKline. Priorix-Tetra (measles, mumps, rubella and varicella vaccine (live): summary of product characteristics. GlaxoSmithKline, 2007